GSK Q3 2026 Earnings Call Transcript
GSK (NYSE:GSK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Stocks · News reference
GSK Plans to Nearly Double Clinical-Stage Cancer Drug Pipeline in 2027
GSK has announced plans to significantly expand its oncology research and development efforts by nearly doubling the number of cancer drug candidates in clinical trials by 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
GSK Reports Strong Third Quarter 2026 Financial Results
GSK reported third-quarter 2026 results, with core earnings per share of 54.6 pence, exceeding analyst consensus of 50.4 pence, driven by strong performance in its Specialty Medicines portfolio.
GSK Announces Director/PDMR Shareholding Transaction
GSK reported that Maya Martinez-Davis, President of US operations, acquired 9.324 notional American Depositary Shares (ADS) on October 22, 2026.